Joinn Laboratories(China)Co (603127) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥145.13 Million ≈ $21.24 Million USD) by net assets (CN¥8.12 Billion ≈ $1.19 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Joinn Laboratories(China)Co - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Joinn Laboratories(China)Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Joinn Laboratories(China)Co balance sheet liabilities for a breakdown of total debt and financial obligations.
Joinn Laboratories(China)Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Joinn Laboratories(China)Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
-0.014x |
|
Brickworks Ltd
AU:BKW
|
0.018x |
|
Nelnet Inc
NYSE:NNI
|
0.031x |
|
TUI AG
XETRA:TUI1
|
-0.618x |
|
Hengan International Group Company Limited
F:HGNC
|
0.067x |
|
Beta Technologies, Inc.
NYSE:BETA
|
-0.046x |
|
Westgold Resources Ltd
AU:WGX
|
0.250x |
|
Brighthouse Financial Inc
NASDAQ:BHF
|
0.018x |
Annual Cash Flow Conversion Efficiency for Joinn Laboratories(China)Co (2012–2024)
The table below shows the annual cash flow conversion efficiency of Joinn Laboratories(China)Co from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Joinn Laboratories(China)Co.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
CN¥338.93 Million ≈ $49.60 Million |
0.042x | -46.37% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
CN¥647.73 Million ≈ $94.78 Million |
0.078x | -34.02% |
| 2022-12-31 | CN¥8.19 Billion ≈ $1.20 Billion |
CN¥971.07 Million ≈ $142.10 Million |
0.119x | +23.53% |
| 2021-12-31 | CN¥7.14 Billion ≈ $1.05 Billion |
CN¥685.66 Million ≈ $100.33 Million |
0.096x | -72.58% |
| 2020-12-31 | CN¥1.22 Billion ≈ $179.13 Million |
CN¥428.39 Million ≈ $62.69 Million |
0.350x | +95.48% |
| 2019-12-31 | CN¥827.26 Million ≈ $121.05 Million |
CN¥148.09 Million ≈ $21.67 Million |
0.179x | -33.76% |
| 2018-12-31 | CN¥651.52 Million ≈ $95.34 Million |
CN¥176.08 Million ≈ $25.77 Million |
0.270x | +25.61% |
| 2017-12-31 | CN¥557.79 Million ≈ $81.62 Million |
CN¥120.01 Million ≈ $17.56 Million |
0.215x | -52.89% |
| 2016-12-31 | CN¥260.18 Million ≈ $38.07 Million |
CN¥118.82 Million ≈ $17.39 Million |
0.457x | -10.43% |
| 2015-12-31 | CN¥208.35 Million ≈ $30.49 Million |
CN¥106.23 Million ≈ $15.54 Million |
0.510x | -1.55% |
| 2014-12-31 | CN¥159.07 Million ≈ $23.28 Million |
CN¥82.38 Million ≈ $12.05 Million |
0.518x | +3.63% |
| 2013-12-31 | CN¥121.89 Million ≈ $17.84 Million |
CN¥60.91 Million ≈ $8.91 Million |
0.500x | +143.98% |
| 2012-12-31 | CN¥99.27 Million ≈ $14.53 Million |
CN¥20.33 Million ≈ $2.98 Million |
0.205x | -- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more